Equities
  • Price (EUR)58.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+7.31%
  • Beta--
Data delayed at least 15 minutes, as of Aug 04 2021 19:41 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Centene Corporation is a multi-national healthcare company. The Company provides services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. It also provides education and outreach programs to inform and assist members in accessing appropriate healthcare services. It operates through two segments: Managed Care and Specialty Services. The Managed Care segment provides health plan coverage to individuals through government subsidized and commercial programs. Its Specialty Services segment includes companies offering diversified healthcare services and products to its Managed Care segment and other external customers. It provides a range of healthcare products and services, primarily through Medicaid, Medicare and commercial products.

  • Revenue in USD (TTM)118.39bn
  • Net income in USD720.00m
  • Incorporated2001
  • Employees71.30k
  • Location
    Centene Corp7700 Forsyth BlvdST. LOUIS 63105-1807United StatesUSA
  • Phone+1 (314) 725-4477
  • Fax+1 (302) 655-5049
  • Websitehttps://www.centene.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CNC:NYQ since
announced
Transaction
value
Magellan Health IncAnnounced04 Jan 202104 Jan 2021Announced15.09%2.49bn
PANTHERx Rare LLCDeal completed15 Dec 202015 Dec 2020Deal completed15.67%--
Apixio IncAnnounced09 Nov 202009 Nov 2020Announced1.71%--
Data delayed at least 15 minutes, as of Aug 04 2021 23:30 BST.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.